Aurobindo Pharma Limited (NSE:AUROPHARMA)

Aurobindo Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	82,355	33,935	43,963	41,625	53,735
Short-Term Investments	0.1	29,329	18,364	4,038	2,580
Trading Asset Securities	-	0.1	0.1	0.1	0.2
Cash & Short-Term Investments	82,355	63,264	62,327	45,663	56,315
Cash Growth	30.18%	1.50%	36.49%	-18.92%	98.32%
Accounts Receivable	57,459	48,167	44,664	40,123	35,033
Other Receivables	-	5,150	5,356	3,619	4,979
Receivables	57,615	53,446	50,144	43,869	40,155
Inventory	105,437	98,082	85,112	75,539	90,266
Other Current Assets	26,218	27,265	17,874	16,157	11,500
Total Current Assets	271,625	242,056	215,457	181,227	198,235
Property, Plant & Equipment	154,554	142,849	124,918	106,660	93,155
Long-Term Investments	2,517	3,216	3,917	6,183	4,312
Goodwill	6,180	5,952	5,961	4,754	4,289
Other Intangible Assets	36,207	32,874	31,279	29,587	25,546
Long-Term Accounts Receivable	1,083	-	-	-	-
Long-Term Deferred Tax Assets	12,930	12,126	6,775	2,886	4,527
Long-Term Deferred Charges	-	1,941	1,980	1,792	1,361
Other Long-Term Assets	12,686	9,643	8,558	6,065	7,042
Total Assets	497,850	450,715	398,900	339,217	338,540
Accounts Payable	41,889	44,542	38,713	27,031	27,947
Accrued Expenses	-	17,924	16,378	12,165	14,918
Short-Term Debt	-	41,685	42,304	21,178	48,038
Current Portion of Long-Term Debt	63,800	117.8	121.3	57.3	-
Current Portion of Leases	819.8	798.8	1,032	1,599	1,006
Current Income Taxes Payable	2,849	2,490	2,116	580.3	2,104
Current Unearned Revenue	-	2,703	3,889	5,679	110.3
Other Current Liabilities	37,466	11,731	10,385	13,272	12,528
Total Current Liabilities	146,823	121,991	114,938	81,560	106,651
Long-Term Debt	15,617	21,349	6,190	2,492	1,685
Long-Term Leases	2,392	2,525	3,215	3,186	2,662
Long-Term Unearned Revenue	-	363.5	-	-	-
Long-Term Deferred Tax Liabilities	3,033	3,566	3,896	4,110	5,746
Other Long-Term Liabilities	3,516	1,665	1,491	1,524	2,052
Total Liabilities	171,380	152,207	130,381	93,477	119,250
Common Stock	580.8	585.9	585.9	585.9	585.9
Additional Paid-In Capital	-	4,179	4,179	4,179	4,179
Retained Earnings	-	276,146	247,236	233,322	209,499
Comprehensive Income & Other	325,952	17,517	16,398	7,674	5,035
Total Common Equity	326,533	298,428	268,399	245,760	219,299
Minority Interest	-63.9	80	120	-19.3	-8.8
Shareholders' Equity	326,469	298,508	268,519	245,741	219,290
Total Liabilities & Equity	497,850	450,715	398,900	339,217	338,540
Total Debt	82,629	66,476	52,862	28,513	53,391
Net Cash (Debt)	-273.7	-3,213	9,465	17,150	2,924
Net Cash Growth	-	-	-44.81%	486.55%	-
Net Cash Per Share	-0.47	-5.48	16.15	29.27	4.99
Filing Date Shares Outstanding	580.64	585.94	585.94	585.94	585.94
Total Common Shares Outstanding	580.64	585.94	585.94	585.94	585.94
Working Capital	124,801	120,065	100,519	99,667	91,585
Book Value Per Share	562.37	509.32	458.07	419.43	374.27
Tangible Book Value	284,146	259,602	231,159	211,419	189,464
Tangible Book Value Per Share	489.37	443.05	394.51	360.82	323.35
Land	-	8,686	8,303	6,518	2,860
Buildings	-	46,978	32,564	25,645	24,177
Machinery	-	119,040	88,308	76,809	67,543
Construction In Progress	-	27,394	44,964	29,376	24,289

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.